Figure 1. Sagittal proton density magnetic resonance image of the knee reveals a lobulated heterogeneous mass in the lateral head of the gastrocnemius muscle. High signal consistent with edema is seen in the surrounding muscle.
Figure 2. Tan-white, vaguely lobulated gross appearance of the soft tissue tumor with a gelatinous cut surface and focal areas of cystic hemorrhage. Scale is in centimeters.
Figure 3. Section reveals small rounded tumor cells in cords and sheets embedded within an abundant extracellular myxoid matrix (hematoxylin-eosin, original magnification ×10).
A diagnosis of extraskeletal myxoid chondrosarcoma was rendered based on histologic findings. Extraskeletal myxoid chondrosarcomas are rare malignant soft tissue neoplasms that are usually seen in patients older than 35 years but can be seen in children.1 As in this case, most are deep seated and are located primarily in the musculature of the extremities. The thigh and popliteal fossa are the most common sites, and the male-female patient ratio is 2:1. Our patient had a typical presentation of nonspecific signs and symptoms.
Typically well-circumscribed, extraskeletal myxoid chondrosarcomas are commonly encapsulated by a rim of fibrous tissue. The abundant myxoid matrix gives the cut surface a gelatinous appearance. The degree of cellularity is variable; less well-differentiated, highly cellular tumors generally have less extracellular matrix and behave more aggressively. As illustrated in this case, the neoplastic cells characteristically are epithelioid to spindly and contain centrally placed, uniformly round to oval, hyperchromatic nuclei and clear to vacuolated eosinophilic cytoplasm. A peripheral rim of eosinophilic cytoplasm can be distinctive, suggesting chondroblastic differentiation. The extracellular matrix stains deeply with Alcian blue; in contrast to myxomas and parachordomas, this staining reaction is resistant to hyaluronidase.
Immunohistochemical studies classically result in positive reactions for S100 protein and vimentin and negative staining for epithelial markers such as epithelial membrane antigen and cytokeratins. However, a recent report indicates that S100 immunopositivity is less common in extraskeletal myxoid chondrosarcomas than generally accepted.2 Ultrastructural features characteristically include distinctive aggregates of microtubules within the rough endoplasmic reticulum. Distinctive, nonmicrombular, lamellar inclusions have also been described.3 Although not found in this case, cytogenetic studies characteristically reveal alterations of chromosomes 9 and 22, t(9;22)(q22-q31;q11-q22). Molecular analysis has shown this translocation to represent fusion of the EWS gene at 22q12 to a novel orphan nuclear receptor gene at 9q22.4
Differential diagnoses include other myxoid neoplasms such as bony myxoid chondrosarcoma, myxoid liposarcoma, chordoma, and parachordoma. Myxoid chondrosarcomas of bone have an identical histologic appearance, necessitating a complete radiologic evaluation to exclude primary bone disease. The presence of lipoblasts and a distinctive plexiform vascularity distinguish myxoid liposarcomas from this neoplasm. Absence of stainable extracellular mucin using Alcian blue after treatment with hyaluronidase is a differentiating feature of myxochondromas, chordomas, parachordomas, and myxoid liposarcomas.
Clinically, extraskeletal myxoid chondrosarcomas are considered to be relatively slow-growing tumors with a long-term propensity for recurrence and metastasis. In a 10-year follow-up study of 10 patients, Saleh et al5 reported metastasis or recurrence in all patients and death from disease in 7. In a larger series, Meiss and Martz6 found a 53% recurrence rate and a 44% metastatic rate, with 73% of the patients alive after 10 years. In a pediatric series, 5 of 7 patients were dead within months after diagnosis.1 The lungs, soft tissues, and lymph nodes are the most common sites of metastasis. The treatment of choice is wide local excision, and a good response to radiation therapy has been observed.7 Resistance to standard soft tissue sarcoma chemotherapy has been demonstrated.8
Accepted for publication September 1, 1997.
Corresponding author: David M. Parham, MD, Slot 820, Arkansas Children's Hospital, 800 Marshall St, Little Rock, AR 72202 (e-mail: ParhamDavidM@exchange.uams.edu).
Thank you for submitting a comment on this article. It will be reviewed by JAMA Pediatrics editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.